Ajanta Pharma Standalone June 2023 Net Sales at Rs 1,014.58 crore, up 19.32% Y-o-Y
July 28, 2023 / 19:23 IST
Reported Standalone quarterly numbers for Ajanta Pharma are:Net Sales at Rs 1,014.58 crore in June 2023 up 19.32% from Rs. 850.29 crore in June 2022.
Quarterly Net Profit at Rs. 212.04 crore in June 2023 up 41.01% from Rs. 150.37 crore in June 2022.
EBITDA stands at Rs. 308.36 crore in June 2023 up 39.07% from Rs. 221.73 crore in June 2022.
Ajanta Pharma EPS has increased to Rs. 16.84 in June 2023 from Rs. 11.74 in June 2022.
| Ajanta Pharma shares closed at 1,552.55 on July 27, 2023 (NSE) and has given 28.90% returns over the last 6 months and 22.02% over the last 12 months. |
| Ajanta Pharma | | Standalone Quarterly Results | in Rs. Cr. |
|
| Jun'23 | Mar'23 | Jun'22 | | Net Sales/Income from operations | 1,014.58 | 848.86 | 850.29 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 1,014.58 | 848.86 | 850.29 | | EXPENDITURE | | Consumption of Raw Materials | 217.81 | 231.89 | 195.05 | | Purchase of Traded Goods | 39.46 | 39.22 | 33.43 | | Increase/Decrease in Stocks | 34.40 | -6.03 | 32.09 | | Power & Fuel | -- | -- | -- | | Employees Cost | 196.30 | 207.06 | 166.92 | | Depreciation | 32.24 | 32.11 | 30.75 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 249.71 | 232.19 | 236.49 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 244.66 | 112.42 | 155.56 | | Other Income | 31.46 | 36.75 | 35.42 | | P/L Before Int., Excpt. Items & Tax | 276.12 | 149.17 | 190.98 | | Interest | 0.75 | 1.21 | 0.63 | | P/L Before Exceptional Items & Tax | 275.37 | 147.96 | 190.35 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 275.37 | 147.96 | 190.35 | | Tax | 63.33 | 30.75 | 39.98 | | P/L After Tax from Ordinary Activities | 212.04 | 117.21 | 150.37 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 212.04 | 117.21 | 150.37 | | Equity Share Capital | 25.27 | 25.27 | 25.71 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 16.84 | 9.15 | 11.74 | | Diluted EPS | 16.84 | 9.15 | 11.74 | | EPS After Extra Ordinary | | Basic EPS | 16.84 | 9.15 | 11.74 | | Diluted EPS | 16.84 | 9.15 | 11.74 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
